Gravier Pierre 4

What Happened
Pierre Gravier, Chief Financial Officer of PTC Therapeutics (PTCT), sold 2,992 shares on 2026-02-18 at $69.36 per share, generating proceeds of approximately $207,525. The filing indicates the sale was an automatic “sell to cover” to satisfy tax withholding obligations tied to the vesting of previously granted RSUs.

Key Details

• Transaction date and price: 2026-02-18, 2,992 shares at $69.36 each.
• Total proceeds: ~$207,525.
• Shares owned after transaction: not specified in the submitted Form 4.
• Footnote: The shares were automatically sold under an irrevocable sell-to-cover election to satisfy tax withholding for the vesting of 4,750 RSUs from a Feb 15, 2024 grant of 19,000 RSUs and 1,550 RSUs from a Feb 15, 2024 grant of 3,100 RSUs.
• Filing: Report filed on 2026-02-20 (appears timely relative to the 2026-02-18 transaction).

Context
This was a tax-withholding sale tied to RSU vesting (not a discretionary open-market divestiture). Such automatic sell-to-cover transactions are common and generally reflect routine tax obligations rather than a direct statement about the insider’s view of the company’s stock.